What We're Reading: Page 117
Industry reads hand-picked by our editors
Jul 22, 2022
-
Science
Potential fabrication in research images threatens key theory of Alzheimer’s disease
-
STAT
Evusheld protects the vulnerable from Covid. Why are so few using it?
-
Kaiser Health News
Parents Become Drug Developers to Save Their Children’s Lives
-
Endpoints News
OrbiMed-backed Silverback, three months after hacking the pipeline, reverse-merges with small allergy biotech
Jul 21, 2022
Jul 20, 2022
-
Politico
House, Senate duel over FDA user fee bills
-
Bloomberg
Monkeypox Treatments Aren’t Getting Enough Scrutiny
-
Associated Press
FDA weighs oversight changes after formula, Juul troubles
-
FiercePharma
Novartis shelves an FDA submission for tislelizumab
Jul 19, 2022
-
The Boston Business Journal
Biogen's Mass. headcount falls by 300 in 10 months
-
The Boston Globe
More lab space: French pharma Servier is growing its cancer business in Seaport
-
Evaluate Vantage
Unpacking Royalty Pharma
-
Reuters
As COVID patent war rages on, pharma group seeks fairer future access
Jul 18, 2022
-
The Wall Street Journal
Merck Deal for Seagen Seen as Unlikely by Earnings Release
-
Stat News
Biotech executives pull in some of health care's biggest paydays
-
Kaiser Health News
FTC Official: Antitrust Push in Health Care Must Focus on a Merger’s ‘Human Impact’
Jul 15, 2022
-
Kaiser Health News
As Big Pharma Loses Interest in New Antibiotics, Infections Are Only Growing Stronger
-
Reuters
After bruising year, GSK approaches consumer split in better health
-
Politico
Manchin rejects climate, tax elements of party-line Dem bill
-
Bloomberg
Chinese Cancer Drugs Biotech Cstone Pharmaceuticals Considers Sale
Previous
